This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

17 Mar 2011

Amylin & Takeda Stop PhII Obesity Study

Amylin and Takeda have suspended a mid-stage clinical trial of a combination obesity treatment.

Amylin Pharmaceuticals Inc. and Takeda Pharmaceutical Co. Ltd. said Wednesday they have suspended a Phase II trial of their obesity drug, a combination of diabetes drug pramlintide and analogue hormone metreleptin. The study was halted for the companies to investigate a new antibody-related laboratory with metreleptin treatment in two patients who participated in a previously completed clinical study of obesity.


"The safety of patients in our clinical programs is of paramount concern to the companies. We have taken this precaution so that we can thorou

Related News